Raza M Alvi1, Anne M Neilan2, Noor Tariq3, Malek O Hassan4, Magid Awadalla4, Lili Zhang4, Maryam Afshar5, Adam Rokicki4, Connor P Mulligan4, Virginia A Triant6, Markella V Zanni7, Tomas G Neilan8. 1. Cardiac MR PET CT Program, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Bronx-Lebanon Hospital Center of Icahn School of Medicine at Mount Sinai, Bronx, New York. 2. Division of Infectious Diseases, Department of Medicine and Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 3. Yale New Haven Hospital of Yale University School of Medicine, New Haven, Connecticut. 4. Cardiac MR PET CT Program, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 5. Bronx-Lebanon Hospital Center of Icahn School of Medicine at Mount Sinai, Bronx, New York. 6. Divisions of Infectious Diseases and General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 7. Program in Nutritional Metabolism, Harvard Medical School, Boston, Massachusetts. 8. Cardiac MR PET CT Program, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: tneilan@mgh.harvard.edu.
Abstract
OBJECTIVES: The aim of this study was to determine the incidence of sudden cardiac death (SCD) among persons living with human immunodeficiency virus infection (PHIV) with heart failure (HF), who were hospitalized for HF, and the risk factors associated with it. BACKGROUND: HF is associated with an increased risk for SCD. PHIV are at heightened risk for HF. METHODS: This was a retrospective study of 2,578 patients hospitalized with HF from a single academic center, of whom 344 were PHIV. The outcome of interest was SCD. Subgroup analyses were performed by strata of viral load (VL) and left ventricular ejection fraction (LVEF) <35%, 35% to 49%, and ≥50%. RESULTS: Of 2,578 patients with HF, 2,149 (86%) did not have implantable cardioverter-defibrillators; of these, there were 344 PHIV and 1,805 uninfected control subjects. Among PHIV with HF, 313 (91%) were prescribed antiretroviral therapy and 64% were virally suppressed. There were 191 SCDs over a median follow-up period of 19 months. Compared with control subjects, PHIV had a 3-fold increase in SCD (21.0% vs. 6.4%; adjusted odds ratio: 3.0; 95% confidence interval: 1.78 to 4.24). Among PHIV, cocaine use, lower LVEF, absence of beta-blocker prescription, and VL were predictors of SCD. The SCD rate among PHIV with undetectable VL was similar to the rate among uninfected subjects. Similar findings were observed by LVEF strata. Among PHIV with HF without conventional indications for an implantable cardioverter-defibrillator, the rate of SCD was 10% per year. CONCLUSIONS: PHIV hospitalized with HF are at a markedly increased risk for SCD. SCD risk was increased in patients with lower LVEFs, lower CD4 counts, and higher VL.
OBJECTIVES: The aim of this study was to determine the incidence of sudden cardiac death (SCD) among persons living with human immunodeficiency virus infection (PHIV) with heart failure (HF), who were hospitalized for HF, and the risk factors associated with it. BACKGROUND: HF is associated with an increased risk for SCD. PHIV are at heightened risk for HF. METHODS: This was a retrospective study of 2,578 patients hospitalized with HF from a single academic center, of whom 344 were PHIV. The outcome of interest was SCD. Subgroup analyses were performed by strata of viral load (VL) and left ventricular ejection fraction (LVEF) <35%, 35% to 49%, and ≥50%. RESULTS: Of 2,578 patients with HF, 2,149 (86%) did not have implantable cardioverter-defibrillators; of these, there were 344 PHIV and 1,805 uninfected control subjects. Among PHIV with HF, 313 (91%) were prescribed antiretroviral therapy and 64% were virally suppressed. There were 191 SCDs over a median follow-up period of 19 months. Compared with control subjects, PHIV had a 3-fold increase in SCD (21.0% vs. 6.4%; adjusted odds ratio: 3.0; 95% confidence interval: 1.78 to 4.24). Among PHIV, cocaine use, lower LVEF, absence of beta-blocker prescription, and VL were predictors of SCD. The SCD rate among PHIV with undetectable VL was similar to the rate among uninfected subjects. Similar findings were observed by LVEF strata. Among PHIV with HF without conventional indications for an implantable cardioverter-defibrillator, the rate of SCD was 10% per year. CONCLUSIONS: PHIV hospitalized with HF are at a markedly increased risk for SCD. SCD risk was increased in patients with lower LVEFs, lower CD4 counts, and higher VL.
Authors: Adeel A Butt; Chung-Chou Chang; Lewis Kuller; Matthew Bidwell Goetz; David Leaf; David Rimland; Cynthia L Gibert; Krisann K Oursler; Maria C Rodriguez-Barradas; Joseph Lim; Lewis E Kazis; Stephen Gottlieb; Amy C Justice; Matthew S Freiberg Journal: Arch Intern Med Date: 2011-04-25
Authors: Zian H Tseng; Eric A Secemsky; David Dowdy; Eric Vittinghoff; Brian Moyers; Joseph K Wong; Diane V Havlir; Priscilla Y Hsue Journal: J Am Coll Cardiol Date: 2012-05-22 Impact factor: 24.094
Authors: James McCord; Hani Jneid; Judd E Hollander; James A de Lemos; Bojan Cercek; Priscilla Hsue; W Brian Gibler; E Magnus Ohman; Barbara Drew; George Philippides; L Kristin Newby Journal: Circulation Date: 2008-03-17 Impact factor: 29.690
Authors: Carlos Rangel; Richard G Shu; Lawrence D Lazar; Eric Vittinghoff; Priscilla Y Hsue; Gregory M Marcus Journal: Arch Intern Med Date: 2010-05-24
Authors: Virginia A Triant; Susan Regan; Hang Lee; Paul E Sax; James B Meigs; Steven K Grinspoon Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: R A Lange; R G Cigarroa; E D Flores; W McBride; A S Kim; P J Wells; J B Bedotto; R S Danziger; L D Hillis Journal: Ann Intern Med Date: 1990-06-15 Impact factor: 25.391
Authors: Andrew N Phillips; Andrew Carr; Jacquie Neuhaus; Fehmida Visnegarwala; Ronald Prineas; William J Burman; Ian Williams; Fraser Drummond; Daniel Duprez; Waldo H Belloso; Frank-Detlef Goebel; Birgit Grund; Angelos Hatzakis; Jose Vera; Jens D Lundgren Journal: Antivir Ther Date: 2008
Authors: Raza M Alvi; Markella V Zanni; Anne M Neilan; Malek Z O Hassan; Noor Tariq; Lili Zhang; Maryam Afshar; Dahlia Banerji; Connor P Mulligan; Adam Rokicki; Magid Awadalla; James L Januzzi; Tomas G Neilan Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Paari Dominic; Javaria Ahmad; Hajra Awwab; Md Shenuarin Bhuiyan; Christopher G Kevil; Nicholas E Goeders; Kevin S Murnane; James C Patterson; Kristin E Sandau; Rakesh Gopinathannair; Brian Olshansky Journal: Circ Arrhythm Electrophysiol Date: 2021-12-28
Authors: Matthew S Freiberg; Meredith S Duncan; Charles Alcorn; Chung-Chou H Chang; Suman Kundu; Asri Mumpuni; Emily K Smith; Sarah Loch; Annie Bedigian; Eric Vittinghoff; Kaku So-Armah; Priscilla Y Hsue; Amy C Justice; Zian H Tseng Journal: J Am Heart Assoc Date: 2021-09-08 Impact factor: 6.106
Authors: Amir S Heravi; Lacey H Etzkorn; Jacek K Urbanek; Ciprian M Crainiceanu; Naresh M Punjabi; Hiroshi Ashikaga; Todd T Brown; Matthew J Budoff; Gypsyamber D'Souza; Jared W Magnani; Frank J Palella; Ronald D Berger; Katherine C Wu; Wendy S Post Journal: Circulation Date: 2019-11-11 Impact factor: 29.690
Authors: Katherine C Wu; Sabina A Haberlen; Michael W Plankey; Frank J Palella; Damani A Piggott; Gregory D Kirk; Joseph B Margolick; Wendy S Post Journal: Eur Heart J Cardiovasc Imaging Date: 2021-07-20 Impact factor: 6.875
Authors: Kaku So-Armah; Laura A Benjamin; Gerald S Bloomfield; Matthew J Feinstein; Priscilla Hsue; Benson Njuguna; Matthew S Freiberg Journal: Lancet HIV Date: 2020-04 Impact factor: 16.070